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IFN-γExperimental autoimmune encephalomyelitis (EAE) is a murine autoimmune disease used to study multiple
sclerosis (MS), a human inﬂammatory demyelinating disease of the central nervous system. Genistein, an
isoﬂavonoid phytoestrogenic compound found in soy, is known to reverse clinical signs of EAE. Although
genistein has some potential in clinical application, it has some disadvantages related to its chemical struc-
ture, such as rapid in vivo metabolism and a fast decline in serum after oral administration. The present
work investigates the treatment of EAE by using 7-O-tetradecanoyl-genistein (TDG), a more lipophilic analog
of genistein obtained by esteriﬁcation. The clinical course of EAE was investigated in C57Bl/6 mice immu-
nized with myelin oligodendrocyte glycoprotein peptide (MOG)35–55 in complete Freund's adjuvant supple-
mented with Mycobacterium tuberculosis H37RA. After 14 days of MOG immunization, mice were treated
with TDG for seven days. Numbers of IL-17-producing cells and Foxp3 by CD4+ T cells and CTLA-4 expression
by CD3+ T cells from brain were determined by ﬂow cytometry. Levels of IL-6, IFN-γ and IL-10 were evalu-
ated by ELISA. Brain sections were stained by hematoxylin and eosin method. The data obtained indicate that
TDG treatment ameliorates the clinical signs of EAE, which correlates with a decrease of IL-17-producing cells
and an increase in Foxp3+CD4+ cells in the brain. TDG is also shown to enhance IL-10 production and CTLA-4
expression and to reduce IFN-γ and IL-6. Altogether, these ﬁndings suggest an immunomodulatory therapeu-
tic role for TDG in EAE and multiple sclerosis.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory demyelinating
disease that affects the central nervous system (CNS) [1,2]. Experi-
mental autoimmune encephalomyelitis (EAE) is a model for the
study of MS. Cytokines produced by T-helper 1 (Th1) cells, such as
IFN-γ, were considered primarily responsible for the induction of
the inﬂammatory process in CNS during the development of MS and
EAE [3,4]. The importance of T-helper 17 (Th17) cells in this process
has been described [5–7]. Th17 can disrupt the blood–brain barrier
by the action of IL-17 [8]. Studies suggest that blockage or neutraliza-
tion of IL-17 could be a therapeutic strategy to improve the clinicalMicrobiology and Immunology,
e Fora, 36036-900, Juiz de Fora,
.
vier OA license.signs of EAE, highlighting the importance of IL-17 in the development
of EAE [6,8]. However, regulatory T cells (Tregs) have been also
reported in studies of EAE as an important cell population which pre-
vents and restrains the EAE development, mainly because of IL-10
production [9,10].
Genistein is an isoﬂavonoid derived from soy that can affect many
different cellular mechanisms such as the inhibition of tyrosine ki-
nases. It increases the activity of antioxidant enzymes and decreases
the production of pro-inﬂammatory molecules by an inhibitory effect
on the classical NF-κB activation factor, known to play a critical role in
inﬂammation, immune modulation and cell proliferation [11–13].
Genistein has been shown to down-modulate the pro-inﬂammatory
cytokines such as IFN-γ, IL-12 and TNF-α, and to reverse clinical
signs of EAE [14]. Although genistein has some potential clinical
application, it has some disadvantages related to its chemical struc-
ture, such as rapid in vivo metabolism and a fast decline in serum
after oral administration [15,16]. The esteriﬁcation in vivo of genis-
tein could be responsible for the increase of biological activity [17].
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ity and biological activity is frequently observed [18,19]. In this work,
a novel analog of genistein, the 7-O-tetradecanoyl-genistein (TDG),
was developed using esteriﬁcation in vitro to bypass the in vivo pro-
cessing, which favors biological activity and increased lipid solubility.
The aim of this study was to evaluate the effect of TDG treatment on
IL-17-producers and Foxp3 expression by CD4+ T cells. Levels of IL-6,
IFN-γ and IL-10 in brain homogenates after TDG treatment were also
investigated.
2. Materials and methods
2.1. Chemical compounds
7-O-tetradecanoyl-genistein (TDG) was synthesized as shown in
Fig. 1. The genistein ester can be easily obtained, in high yield, by
the esteriﬁcation reaction of genistein with tetradecanoic acid in the
presence of dicyclohexylcarbodiimide (DCC) and dimethylaminopyr-
idine (DMAP) in dichloromethane. Genistein (log (P): 1.4) (Sigma, St.
Louis, MO, USA) and its analog TDG (log (P): 6.3) were solubilized in
the DMSO (Sigma), never exceeding 0.1% (v/v), and diluted in sterile
phosphate buffered saline (PBS). The partition coefﬁcient P (log (P))
of genistein and TDG represents the hydrophobic properties of these
compounds.
2.2. Animals
Female C57Bl/6 mice 4–6 weeks old were obtained from the
animal care facilities of the Federal University of Juiz de Fora (UFJF)
and maintained in microisolator cages. All procedures were in
accordance with the principles of the Brazilian Code for the Use of
Laboratory Animals. Mice were used between 8 and 10 weeks of age
(n=17 per group). All protocols involving mice handling were
approved by the committee on the use of laboratory animals from
UFJF (Protocol no. 026/2008).
2.3. EAE induction and TDG treatment
Three groups of 17 mice were subcutaneously (s.c.) immunized at
the tail base with 100 μg of myelin oligodendrocyte glycoprotein
peptide (MOG)35–55, synthesized in the laboratory of Biophysics,
Federal University of São Paulo, emulsiﬁed v/v in complete Freund's
adjuvant (Sigma Chemical Co., Saint Louis, USA) and supplemented
with 400 μg of attenuated Mycobacterium tuberculosis H37RA (Difco,
Detroit, USA). Pertussis toxin 300 ng/animal (Sigma Chemical Co.,
Saint Louis, USA) was injected intraperitoneally (i.p.) on the day of
immunization and 48 h later. One of these immunized groups was
treated with TDG (TDG group) at a dose of 200 mg/kg s.c daily for a
total of seven doses. This treatment was initiated at day 14 post-
immunization (p.i.) [14]. A second immunized group received no
treatment (NT-EAE group). Genistein was used as a reference
compound on the third immunized group (genistein group) at a
dose of 200 mg/kg s.c, because of its proven effects on EAE [14]. A
non-immunized control group (CT group) was s.c. injected with
dimethyl sulfoxide (DMSO, Sigma Chemical Co., Saint Louis, USA)
0.1%. Animals were monitored daily and neurological impairment
was quantiﬁed.Fig. 1. Preparation of 7-O-tetradecanoyl-genistein2.4. Clinical assessment
Mice were weighed and the clinical signs of EAE observed daily for
up to 21 days after immunization. The clinical status was assessed
individually according to Table 1 [14]. The ﬁnal clinical score was
obtained adding all individual scores assessed.
2.5. Isolation of brain mononuclear cells
Twenty-one days after infection, groups of mice (n=8) were
euthanized under anesthesia (i.p) and perfused through the left ven-
tricle with phosphate saline buffer (PBS). Brains were macerated and
ﬁltrated using 70 μm cell strainer (BD Biosciences, Bedford, USA) in
RPMI medium 1640 (Gibco, Grand Island, USA) with 10% fetal bovine
serum (FBS) (Gibco, Grand Island, USA). Dispersed brain cells were
incubated in RPMI containing 2 mgof collagenase D (Roche,Mannheim,
Germany) at 37 °C for 45 min. Brain mononuclear cells were collected
after Percoll density gradient centrifugation [20] and washed with
staining buffer (PBS, 1% FBS, 0.1% sodium azide). The cell pellet was
suspended in ACK solution, centrifuged at 350×g for 5 min, and
suspended in staining buffer for cytometry analysis.
2.6. Cytometry analysis
Brain cells were incubated with anti-mouse CD3-PerCP, anti-mouse
CTLA-4-PE or anti-mouse CD4-PerCP (BD Biosciences Pharmingen, San
Diego, USA). After 30 min at 4 °C, cells were washed in staining buffer
and permeabilized with BD Pharmingen Fix/Perm solution, washed in
BD Pharmingen Perm/Wash Buffer, and then stained with anti-mouse
IL-10-PE, anti-mouse IL-17-Alexa Fluor 488, anti-mouse transcription
factor forkhead box P3 (Foxp3)-Alexa Fluor 488 (BD Biosciences
Pharmingen, San Diego, USA) and analyzed using a FACScalibur ﬂow
cytometer and CellQuest software (Becton Dickinson, San Diego, USA).
2.7. Cytokine production
Brains from 5mice per group were removed and hemispheres were
homogenized (100 mg/ml) in extraction solution containing 0.4 M
NaCl, 0.05% Tween 20 (Merck & Co., Inc., Whitehouse Station, USA),
0.5% bovine serumalbumin (BSA), 0.1 Mphenylmethylsulfonyl ﬂuoride
(PMSF), 0.1 M benzethonium chloride, 10 mM ethylenediaminetetraa-
cetic acid (EDTA) and 20 kIU/ml aprotinin (Sigma Chemical Co., Saint
Louis, USA). The homogenate was centrifuged at 2000×g for 15 min
at 4 °C and supernatants were collected to determine the concentration
of IL-6, IL-17 and IFN-γ. Cytokine production was assayed by ELISA
using commercially available antibodies according to the manufac-
turer's instructions (BD Biosciences Pharmingen, San Diego, USA).
2.8. Histological analysis
To assess the degree of CNS inﬂammation, 4 mice per group were
euthanized under anesthesia on day 21 post-immunization. The brain
was removed quickly. A portion of brain sample was ﬁxed in 10%
neutral buffered formalin and then cut into 5-μm-thick sections.
Tissues were stained with hematoxylin and eosin (H&E) to assess
tissue damage and inﬂammation.(2) by esteriﬁcation reaction of genistein (1).
Table 1
Clinical score assessment.
Part of the body Clinical signs Scorea
Tail No clinical signs 0
Loss of muscle tone in tail 1
Paralysis 2
Hind-limb No clinical signs 0
Weakness of one animal paw 1
Weakness of both animal paws 2
Paralysis of one animal paw 3
Paralysis of both animal paws 4
Front-limb No clinical signs 0
Weakness of any animal paw 1
Paralysis of any animal paw 2
Bladder Continence 0
Incontinence 1
a Numerical score arbitrarily established.
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Results represent at least two independent experiments and are
presented as the mean±SEM. All data were analyzed using Kruskall–
Wallis test (GraphPad Prism 5.00), and the differences were considered
signiﬁcant at pb0.05.3. Results
3.1. TDG treatment improves clinical signs of EAE
The clinical course of EAE was investigated in mice immunized
with MOG35–55 peptide and s.c. treated with TDG at 200 mg/kg for
seven days. EAE severity was recorded daily using a clinical score
scale (Fig. 2). The immunized mice presented signs of EAE such as
loss of muscle tone in tail around 11–12 days after immunization.
On day 14 all immunized mice showed clinical scores including at
least tail paralysis (score=2). At 18th day post-immunization, the
clinical score (2.4±0.24) of the TDG treated mice was lower than
that observed in the NT-EAE group (score=4±0.45). Clinical
evidence of disease in the TDG-treated group peaked at day 15 after
immunization maintaining a low clinical score, while in the NT-EAE
group it peaked at day 17. These clinical score improvements after
TDG treatment were similar to those observed in the genistein
group (Fig. 2).Fig. 2. Clinical score of C57Bl/6 mice immunized with MOG35–55 peptide (n=17 per
group). The clinical signs were registered from day 0 to day 21 post-immunization.
7-O-tetradecanoyl-genistein (TDG) and genistein treatments started at day 14 after
immunization. NT-EAE = untreated control group. Genistein = genistein-treated
group. TDG = TDG-treated group. Each point represents mean±SEM. *pb0.01 of
Genistein versus NT-EAE, and TDG versus NT-EAE.3.2. Cells and cytokines involved in EAE were modulated by TDG
treatment
The number of mononuclear cells isolated from the brains was
obtained to CT group (0.2×105), NT-EAE (7×105), TDG (2.2×105)
and genistein (1.5×105). IL-17-producing Th17 cells play an impor-
tant role in development of EAE [3,8]. To determine the presence of
cells producing IL-17, the brain cells were isolated and stained with
anti-mouse CD4 and anti-mouse IL-17. The percentage of IL-17-
producing cells was higher in the NT-EAE group in comparison to all
other groups. A lower number of IL-17-producing cells in the brain
were observed in the TDG group (Fig. 3A).
IL-6 is involved in the differentiation of Th17 [21]. The concentra-
tion of IL-6 (Fig. 3G) was measured in brain supernatants at day 21
after MOG35–55 immunization. Higher levels of IL-17, IFN-γ and IL-6
(Fig. 3E–G) were observed in the NT-EAE group in relation to the CT
group. After TDG treatment, levels of IL-17, IFN-γ and IL-6 were
lower in comparison to the NT-EAE group (Fig. 3E–G). These results
indicate an inﬂuence of TDG treatment in down-modulation of the
pro-inﬂammatory cytokines, IL-17, IFN-γ and IL-6.
Foxp3 is essential to establish functional Treg cells [22,23]. Treg
cells inhibit autoimmunity and protect against tissue lesions [22,24].
In this study, TDG treatment increased Foxp3+CD4+ cells in levels
similar to the CT group and more than NT-EAE. This up-regulation
was also observed in genistein treated mice (Fig. 3B). In addition,
TDG treatment increased the number of Foxp3+CD4+ T cells in
spleen and lymph node cells, in relation to either the NT-EAE group
or the genistein group (data not shown).
CTLA-4 is a potent down-regulator of T cell immune responses.
Expression of CTLA-4 was associated with Foxp3+ Treg function
[25,26]. A lower percentage of CTLA-4+CD3+ cells were observed in
the NT-EAE group (Fig. 3C). Mice treated with TDG had percentage
of CTLA-4+CD3+ cells similar to the CT group, and high percentage
in comparison to the genistein group (Fig. 3C).
IL-10 is a regulatory cytokine that plays a critical role in control-
ling autoimmune diseases such as EAE [10]. The TDG treatment
increased the percentage of brain CD4+ T cells producing IL-10 in
relation to the NT-EAE group (Fig. 3D). This increase was observed
also in the genistein group as compared with the NT-EAE group
(Fig. 3D).
3.3. TDG treatment reduces cellular inﬁltration at brain of EAE mice
In the histological analysis of slides of tissue from the brain,
stained with H&E, was ﬁrst observed that the induction of EAE led
to the formation of a meningeal inﬂammatory cell inﬁltrate in the
brain of the induced animals (NT-EAE group) compared to the nega-
tive non-induced control group (CT group). The histological sections
of the brain of the CT group (Fig. 4A,B,C) were considered normal,
that is, without the presence of inﬂammatory cell inﬁltrate. In con-
trast all animals in group NT-EAE (Fig. 4D,E,F) showed meningeal
inﬂammatory cell inﬁltrate in the brain. In the analysis of histological
sections of brain of animals treated with the TDG (Fig. 4G,H,I), as well
as in animals treated with the genistein (Fig. 4J,K,L) meningeal
inﬂammatory inﬁltrates were not observed. The general appearance
of the histological sections of brain of the TDG and of the genistein
group is similar to the CT group.
4. Discussion
TDG is a lipophilic analog of genistein obtained by its esteriﬁcation
reaction. The lipophilic character can be calculated by log (P) value,
where compounds with higher log values (P) are more lipophilic.
This increase of lipophilic character of the TDG analog was obtained
by the introduction of a hydrocarbon chain in the genistein com-
pound by means of an esteriﬁcation reaction. The main ﬁndings of
Fig. 3. Expression of intracellular IL-17 (A), Foxp3 (B), IL-10 (D) in brain CD4 T and CTLA-4 in brain CD3 T cells (C) were determined by ﬂow cytometry (n=8mice/group) at day 21
post-immunization with MOG35–55. Cells were stained with ﬂuorescence-conjugated antibodies to IL-17 (Alexa Fluor 488), Foxp3 (Alexa Fluor 488), IL-10 (PE), CD4 (PerCP), CTLA-4
(PE) and CD3 (PerCP). IL-17 (E), IFN-γ (F), and IL-6 (G) were measured by ELISA (n=5 mice/group) in brain homogenates at day 21 post-immunization with MOG35–55. Bars
represent mean±SEM. CT = non-immunized control. NT-EAE = untreated, immunized control. Genistein = immunized group treated with genistein. TDG = immunized
group treated with 7-O-tetradecanoyl-genistein. *pb0.05 versus genistein. **pb0.05 versus NT-EAE.
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course and this correlates with reduction of IL-17-producing cells in
the brain, lower levels of IL-17, IL-6 and IFN-γ, and an increased
number of Foxp3+CD4+ T cells and IL-10 in CNS in comparison to
the NT-EAE group.
To our knowledge this is the ﬁrst study to show the action of a
genistein analog (TDG) in ameliorating the course of EAE. EAE patho-
genesis is mainly attributed to Th17 and its cytokine IL-17 [8]. A
decreased number of IL-17-producing cells were observed in the
TDG and in genistein treated groups. Results presented by others
showed the involvement of IL-17 in disrupting the blood–brain
barrier, an early and central event in EAE pathogenesis [8,27]. IL-17
acts by formation of reactive oxygen species (ROS) that down-
regulate tight junction proteins and activate the endothelial contrac-
tile machinery [8]. Moreover, IL-17-neutralizing antibodies prevented
the blood–brain barrier disruption induced by IL-17 and ameliorated
the EAE course [28]. The development of EAE is signiﬁcantly inhibited
in IL-17 deﬁcient mice. These animals exhibited delayed disease
onset, reduced maximum severity scores, ameliorated histological
changes and early recovery [29].In this work, IL-17 and IL-6 levels in the brain were reduced after
TDG treatment. IL-6 is an important cytokine involved in differentia-
tion of naive T cells to Th17 subsets [21,30,31]. The presence of IL-6 is
decisive to the differentiation of Th17 subsets [21,30,31]. IL-6 has
been shown to drive up-regulation of the transcription factor orphan
nuclear receptor (RORγt) and consequent induction of IL-17 produc-
tion [21]. The IL-6 blockade by treatment with anti-IL-6R inhibits the
development of EAE and Th17 differentiation in inguinal lymph nodes
[31]. Thus, the reduction in IL-6 with TDG treatment may have
favored the decline in production of IL-17. IFN-γ was also inhibited
by TDG treatment. IFN-γ production by Th1 cells correlates with the
seriousness of EAE [3,32,33].Together with Th17 cells, Th1 cells are
considered critical cell population responsible for EAE development,
mainly through IFN-γ production [32,33].
TDG treatment increased the expression of transcription factor
Foxp3 in CD4+ T cells. Foxp3 is essential to establish functional
Tregs [22,23]. The importance of Tregs in suppressing EAE is widely
recognized [34–36]. A decrease of Foxp3-expressing cells has been
observed in the NT-EAE group. Studies have shown that pertussis
toxin used as an adjuvant in the induction of EAE with MOG peptide
Fig. 4. Brains from C57Bl/6 mice immunized with MOG35–55 peptide. The ﬁgures are representative of the histological analysis of each experimental group: CT = non-immunized
group (A, B, C), NT-EAE = immunized untreated group (D, E, F), TDG = immunized group treated with O-tetradecanoyl genistein (G, H, I), genistein=immunized group treated
with genistein (J, K, L), stained with H&E and captured at a magniﬁcation of 20×, 40× and 10×, bar scale=50 μm. In histological sections of brains of the C57Bl/6 belonging to the
group NT-EAE the presence of meningeal inﬂammatory inﬁltrate is observed (arrows) absent in the CT group, without histological alterations. In the treatment with TDG or with
genistein inﬂammatory inﬁltrate was not observed, similar to that observed in the CT group.
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of IL-6 may inhibit the generation of Tregs in favor of Th17 in the
presence of TGF-β [23,24].
Up-regulation of IL-10 was observed after TDG treatment, and was
associated with an increase in the percentage of Foxp3+CD4+ cells.
IL-10 is produced primarily by Treg cells [9]. IL-10 has been shown
to be a critical cytokine that suppresses effector T-cell function
[9,10]. Previous studies have demonstrated that EAE clinical signs
are reduced by a IL-10-dependent mechanism [9,10,39]. In addition,
in this work, an increased expression of CTLA-4 was observed in
TDG-treated group. CTLA-4 is expressed by T lymphocytes and bind
to CD80 and CD86 molecules in antigen-presenting cells (APCs),
competing with the coactivation molecule CD28 [40]. CTLA-4 may
exert a key role in the suppressive function of Foxp3+ Treg cells
[25]. Previous study has shown that increase in CTLA-4 expression
in lymphocytes controls the expansion of encephalitogenic cells in
EAE [41]. Therefore, we can hypothesize that the increased CTLA-4
expression in the TDG-treated group may favor the action of Treg
cells in controlling EAE. However, TDG and genistein act differently
in CTLA-4 expression and further studies are needed to assess this
different modulation.
Histological analysis of brain tissue, from animals belonging to the
experimental groups, demonstrated that the induction of EAE led to
the formation of inﬂammatory cell inﬁltrate in the brain of the NT-
EAE group in relation of the CT-group. Previous studies carrying out
histological analysis of the CNS tissues of animals with EAE often
showed the presence of meningeal inﬂammatory cell inﬁltrate in
the parenchyma of the brain and spinal cord of the animals[36,42–44]. The subarachnoid space is considered the starting
location for entry of cells in the CNS because of the constitutive
expression of chemokine receptors which would facilitate the entry
of inﬂammatory cells, explaining the presence of meningeal inﬂam-
matory cell inﬁltrate in the CNS [45–47].
The results obtained showed a reduction in cell inﬁltration in the
CNS tissues in treatment with the TDG or the genistein, which could
explain the reduction in clinical signs of animals treated with the
TDG. Moreover, the results of this study support the hypothesis that
the worsening of clinical symptoms of EAE is correlated with the
inﬂux of cells in the brain and spinal cord, leading to an increase in
the cells producing IL-17 and IFN-γ.
In conclusion, our ﬁndings suggest that treatment with TDG, a
more lipophilic analog of genistein, improves the clinical signs of
EAE. This correlates with a decrease in IL-17-producing cells and an
increase in Foxp3+CD4+ cells in the brain. TDG is also shown to
enhance IL-10 production and CTLA-4 expression, and to reduce
IFN-γ and IL-6. This study suggests a possible advantage of TDG use
for the treatment of EAE and multiple sclerosis. Further studies are
needed for a better understanding of the immunomodulation process
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